Clinical Trial: Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)

U.S., June 9 -- ClinicalTrials.gov registry received information related to the study (NCT07632898) titled 'Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)' on May 26.

Brief Summary: This is a multicenter, open-label extension (OLE), single-arm study designed to assess the long-term safety and tolerability of oral IKT-001 administered once daily.

Study Start Date: Oct. 23, 2026

Study Type: INTERVENTIONAL

Condition: Pulmonary Arterial Hypertension (PAH)

Intervention: DRUG: IKT-001

IKT-001 tablets for PO administration

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Inhibikase Therapeutics

Published by HT Digital Content Services with permission from Health Daily Digest....